Oral News and Research

RSS

Studies provide new information on diet and blood pressure in kidney disease patients

Three studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on diet and blood pressure in kidney disease patients.

3 Nov 2012

Intensified antibiotic treatment can improve prognosis of patients with TB meningitis

Researchers from the Radboud UMC have conducted the first study globally to show that intensified antibiotic treatment can improve the prognosis of patients with tuberculous (TB) meningitis, the most severe form of TB which carries a mortality of up to 50%.

3 Nov 2012

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.

3 Nov 2012

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.

2 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013. The 90-day proof of concept study is being conducted in type 2 diabetics not well controlled with approved oral anti-diabetic agents.

2 Nov 2012

Malarial drug shows promise in stopping breast cancer

A malarial drug is showing promise in stopping breast cancer before it starts, Mason researchers are discovering during a clinical trial.

2 Nov 2012

Acupuncture shows promise in head and neck patients with xerostomia

Acupuncture significantly relieves the symptoms of xerostomia, or dry mouth, compared with oral care education in patients who have undergone radical or adjuvant radiotherapy for head and neck cancer, indicate the results of a randomized crossover trial.

1 Nov 2012

Nisin may slow or prevent squamous cell head and neck cancers

Nisin, a common food preservative, may slow or stop squamous cell head and neck cancers, a University of Michigan study found.

1 Nov 2012

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

Roundup: Dallas approves stipend for gay, unmarried employees; Federal judge says Milwaukee can raise retiree contribution

Dallas County will give a stipend to unmarried and gay employees who provide health care benefits to their partners. County commissioners approved the new program in a narrow 3-2 vote, which was split along party lines. Democratic commissioners hailed the move as a way to attract and retain talent, embrace the county's diversity and compete against private companies who already provide domestic partner benefits.

1 Nov 2012

Watson acquires Actavis

Watson Pharmaceuticals, Inc. today announced that it has completed the acquisition of the Actavis Group for EUR 4.25 billion.

1 Nov 2012

Hormone therapy increases risk of heart attack or dying in women with metabolic syndrome

A new analysis of the Women's Health Initiative (WHI) trials show that women who had metabolic syndrome before they started hormone therapy had a greatly increased risk of heart attack or dying of heart disease. Women who didn't have metabolic syndrome beforehand showed no increased risk.

31 Oct 2012

Oral News and Research

Studies provide new information on diet and blood pressure in kidney disease patients

Intensified antibiotic treatment can improve prognosis of patients with TB meningitis

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

TransTech Pharma to complete TTP054 Phase 2 trial on type 2 diabetes

Malarial drug shows promise in stopping breast cancer

Acupuncture shows promise in head and neck patients with xerostomia

Nisin may slow or prevent squamous cell head and neck cancers

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

Roundup: Dallas approves stipend for gay, unmarried employees; Federal judge says Milwaukee can raise retiree contribution

Watson acquires Actavis

Hormone therapy increases risk of heart attack or dying in women with metabolic syndrome

Symposium to discuss latest scientific and clinical advances in treating non-Hodgkins lymphoma

Orexo initiates OX51 Phase II trial in patients undergoing prostate biopsy

Poor fitting and inadequate support leading to ineffective use of hearing aids

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News